Instruction for use: Follitpopin beta (Follitropinum beta)

Chemical name:

Follicle-stimulating hormone

Pharmacological group

Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists

Nosological classification (ICD-10)

E23.0 Hypopituitarism

Kalmann's syndrome, Infantilism pituitary, Dwarfism is cerebral-pituitary, Cachexia pituitary, Cachexia diencephalo-pituitary, Anovulatory disorders, Symmonds disease, Secondary hypogonadism in men, Secondary hypogonadotropic hypogonadism, Hypogenitalism, Hypogonadism, Hypogonadism hypogonadotropic, Hypogonadism of the pituitary, Hypogonadism in men, Hypogonadotropic hypogonadism, Hypopituitarism, Pituitary insufficiency, Lack of growth in children with hypopituitarism, Pangypopituitarism, Primary hypogonadism, Primary hypogonadotropic hypogonadism, Shihan Syndrome, Shihina's Syndrome, Symmonds-Glinsky disease, Laron's dwarfism, Sheena's Syndrome, Syndrome of a fertile eunuch

E28.2 Polycystic ovary syndrome

Stein-Levental Syndrome, Polycystic ovary, Polycystic ovary syndrome, Stein-Levental Syndrome, Sclerokrostoznaya disease of the ovaries, Stein-Leventhal syndrome, Polycystic ovary syndrome

N97 Female infertility

Female infertility in anovulation, Hyperprolactinemic infertility, Hyperprolactinaemia with infertility, Endocrine infertility, Infertility due to hypothalamic-pituitary dysfunction, Infertility infertility, Infertility, Infertility on the background of hyperprolactinaemia, Functional infertility, Marriage is infertile, Infertility of ovarian genesis, Stimulation of the growth of a single follicle

Z31.1 Artificial insemination

Fence of egg, ICSI (Intra Cytoplasmic Sperm Injection), Controlled ovarian stimulation, Controlled superovulation, Controlled superovulation in artificial insemination, Treatment of insemination, Fertilization artificial, Premature ovulation, The IVF program, The program of in vitro fertilization, Superovulation

Z31.2 In Vitro Fertilization

Support of the luteal phase in the spontaneous or induced menstrual cycle, Support of the luteal phase during preparation for in vitro fertilization, Reproductive technologies, Superovulation, ECO, In Vitro Fertilization, Controlled superovulation in in vitro fertilization

Pharmacology

The pharmacological action is estrogen-like.

Replenishes the FSH deficiency; Increases the level of sex hormones in the blood. In women, the maturation of follicles in the ovaries (before the pre-ovarian stage), increases the content of estrogens, stimulates the proliferation of the endometrium.

Cmax after IM or SC administration is achieved within 12 hours. Bioavailability is 77%. The level of FSH remains elevated for 24-48 h; T1 / 2 - 12-70 hours (on the average - 40 hours).

Indications

Infertility in women due to hypothalamic-pituitary disorders (hypogonadotropic hypogonadism), inferior maturation of the follicle (deficiency of the yellow body); Polycystic ovary syndrome, refractory to clomiphene citrate therapy, induction of superovulation (in vitro fertilization, embryo transfer, gamete transfer into the fallopian tube, intracytoplasmic sperm injection).

Contraindications

Hypersensitivity, hypertrophy or ovarian cysts, uterine hemorrhages of unclear etiology, pituitary and hypothalamic tumors, uterus, ovaries, mammary glands, fibroids and uterine myomas, abnormalities of genital organs, incompatible with pregnancy, primary ovarian failure, extragenital endocrinopathies due to thyroid tumors and Adrenal glands, thyroid gland diseases, adrenal glands and pituitary gland, marked violations of liver and kidney function, pregnancy, breast-feeding.

Side effects

Ovarian hyperstimulation syndrome (abdominal pain, nausea, diarrhea, development of ovarian cysts, ascites, hydrothorax, thromboembolism, oliguria, hypotension), multiple pregnancy or ectopic pregnancy, fever, arthralgia, mammary gland, skin rash, urticaria, antibodies ( With prolonged use), hyperemia at the injection site.

Interaction

Clomiphene citrate may increase the intensity of ovulation stimulation. The joint use of gonadotropin-releasing hormone agonists requires an increase in dose. Pharmaceutically incompatible (do not mix in one syringe) with other medicines.

Routes of administration

intravenously, subcutaneously

Precautions

During the period of treatment, daily hormonal control and ultrasound for the condition of the developing follicles are necessary (ovarian response can be assessed by cervical index). If there is a threat of the ovarian hyperstimulation syndrome, the treatment stops. It is recommended to constantly change the place of administration.